It is concluded that EAM-2201 has the prospective to cause in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and is particularly evaluated in pooled human liver microsomes.As a result, we conclude that fitting only to good period Attributes, as is completed in most prospective improvement m